The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Post-treatment PET scan is highly predictive of outcome (PFS and OS) in MCL pts treated with R-Hyper-CVAD in the frontline setting regardless of MIPI score.
Anthony R. Mato
Honoraria - Celgene; Millennium; Pharmacyclics
Ewelina Protomastro
No relevant relationships to disclose
Tania Zielonka
No relevant relationships to disclose
Tatyana Feldman
No relevant relationships to disclose
Harry Agress
No relevant relationships to disclose
Mary Timberg
No relevant relationships to disclose
Gabriella Gadaleta
No relevant relationships to disclose
Pritish Bhattacharyya
No relevant relationships to disclose
Alexandria Campaiola
No relevant relationships to disclose
Jakub Svoboda
No relevant relationships to disclose
Susan Stives
No relevant relationships to disclose
Coleen Bejot
No relevant relationships to disclose
Kar Fai Chow
No relevant relationships to disclose
Larysa Jessica Gromko
No relevant relationships to disclose
Andrew Pecora
No relevant relationships to disclose
Andre Goy
No relevant relationships to disclose